Calliditas Therapeutics AB
STO:CALTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
86.45
208.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Calliditas Therapeutics AB
Calliditas Therapeutics AB
Revenue
Calliditas Therapeutics AB
Revenue Peer Comparison
CAMX
IRLAB A
MOB
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Revenue
kr1.6B
|
CAGR 3-Years
1 488%
|
CAGR 5-Years
63%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Revenue
kr1.6B
|
CAGR 3-Years
50%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Revenue
kr2.5B
|
CAGR 3-Years
75%
|
CAGR 5-Years
85%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Revenue
kr5.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
216%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Revenue
kr0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Revenue
kr100k
|
CAGR 3-Years
123%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
Calliditas Therapeutics AB
Revenue Breakdown
Breakdown by Geography
Calliditas Therapeutics AB
|
Total Revenue:
1.2B
SEK
|
|
Europe:
201.9m
SEK
|
|
China, Hong Kong, Macau, Taiwan And Singapore:
27.5m
SEK
|
Breakdown by Segments
Calliditas Therapeutics AB
|
Total Revenue:
1.2B
SEK
|
|
Out-Licensing Of The Product Candidate:
225.3m
SEK
|
|
Performance Of Certain Regulatory Services:
4.1m
SEK
|
See Also
What is Calliditas Therapeutics AB's Revenue?
Revenue
1.6B
SEK
Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Revenue amounts to 1.6B SEK.
What is Calliditas Therapeutics AB's Revenue growth rate?
Revenue CAGR 5Y
63%
Over the last year, the Revenue growth was 39%. The average annual Revenue growth rates for Calliditas Therapeutics AB have been 1 488% over the past three years , 63% over the past five years .
You don't have any saved screeners yet
